Belite Bio, Inc

NasdaqCM:BLTE 주식 보고서

시가총액: US$2.3b

Belite Bio 관리

관리 기준 확인 2/4

Belite Bio CEO는 Tom Lin, Nov2021 에 임명되었습니다 의 임기는 6.67 년입니다. 는 $ 40.06M 가치에 해당하는 회사 주식의 1.72% 직접 소유합니다. 40.06M. 경영진과 이사회의 평균 재임 기간은 각각 3 년과 3 년입니다.

주요 정보

Tom Lin

최고 경영자

n/a

총 보상

CEO 급여 비율n/a
CEO 임기3yrs
CEO 소유권1.7%
경영진 평균 재임 기간3yrs
이사회 평균 재임 기간3yrs

최근 관리 업데이트

Recent updates

We're Interested To See How Belite Bio (NASDAQ:BLTE) Uses Its Cash Hoard To Grow

Sep 26
We're Interested To See How Belite Bio (NASDAQ:BLTE) Uses Its Cash Hoard To Grow

Are Investors Undervaluing Belite Bio, Inc (NASDAQ:BLTE) By 45%?

Jul 03
Are Investors Undervaluing Belite Bio, Inc (NASDAQ:BLTE) By 45%?

We're Hopeful That Belite Bio (NASDAQ:BLTE) Will Use Its Cash Wisely

Mar 20
We're Hopeful That Belite Bio (NASDAQ:BLTE) Will Use Its Cash Wisely

An Intrinsic Calculation For Belite Bio, Inc (NASDAQ:BLTE) Suggests It's 49% Undervalued

Jan 10
An Intrinsic Calculation For Belite Bio, Inc (NASDAQ:BLTE) Suggests It's 49% Undervalued

Belite Bio, Inc's (NASDAQ:BLTE) Intrinsic Value Is Potentially 25% Below Its Share Price

Jul 31
Belite Bio, Inc's (NASDAQ:BLTE) Intrinsic Value Is Potentially 25% Below Its Share Price

We're Not Worried About Belite Bio's (NASDAQ:BLTE) Cash Burn

May 03
We're Not Worried About Belite Bio's (NASDAQ:BLTE) Cash Burn

Belite Bio down 21% after disappointing mid-stage results of rare eye disease candidate

Oct 03

Belite Bio receives approval of begin LBS-008 phase 3 trial in China

Sep 16

Belite Bio adds 15% as pivotal trial for lead asset starts in U.S.

Aug 22

Belite Bio GAAP EPS of -$0.23 beats by $0.05

Aug 12

Belite Bio (NASDAQ:BLTE) Is In A Good Position To Deliver On Growth Plans

Aug 01
Belite Bio (NASDAQ:BLTE) Is In A Good Position To Deliver On Growth Plans

Belite seeks FDA nod to proceed with phase 3 trial of genetic eye disease treatment

Jul 19

CEO

Tom Lin (45 yo)

3yrs

테뉴어

Dr. Yu-Hsin Lin, also known as Tom, MBA MMed PhD (Med) is the founder and has served as Director of Belite Bio Inc since March 2018 and its Chairman and served as the Chief Executive Officer since November...


리더십 팀

이름위치테뉴어보상소유권
Yu-Hsin Lin
Chairman of the Board of Directors & CEO3yrs데이터 없음1.72%
$ 40.1m
Hao-Yuan Chuang
CFO & Director4.6yrs데이터 없음1.01%
$ 23.5m
Nathan Mata
Chief Scientific Officer3yrs데이터 없음데이터 없음
Hendrik Scholl
Chief Medical Officer & Member of Ophthalmology Clinical Advisory Boardless than a year데이터 없음데이터 없음

3.0yrs

평균 재임 기간

45yo

평균 연령

경험이 풍부한 관리: BLTE 의 관리팀은 경험 ( 3 년 평균 재직 기간)으로 간주됩니다.


이사회 구성원

이름위치테뉴어보상소유권
Yu-Hsin Lin
Chairman of the Board of Directors & CEO6.7yrs데이터 없음1.72%
$ 40.1m
Hao-Yuan Chuang
CFO & Director3yrs데이터 없음1.01%
$ 23.5m
Hendrik Scholl
Chief Medical Officer & Member of Ophthalmology Clinical Advisory Boardno data데이터 없음데이터 없음
Frank Holz
Member of Ophthalmology Clinical Advisory Boardno data데이터 없음데이터 없음
Yuan Lu
Independent Director2.6yrs데이터 없음데이터 없음
Quan Dong Nguyen
Member of Ophthalmology Clinical Advisory Boardno data데이터 없음데이터 없음
Michel Michaelides
Member of Ophthalmology Clinical Advisory Boardno data데이터 없음데이터 없음
Wan-Shan Chen
Director3yrs데이터 없음데이터 없음
Hung-Wei Chen
Director3yrs데이터 없음데이터 없음
John Longo
Independent Director2.6yrs데이터 없음데이터 없음
Gary Biddle
Independent Director2.6yrs데이터 없음데이터 없음
Robyn Guymer
Member of Ophthalmology Clinical Advisory Boardno data데이터 없음데이터 없음

3.0yrs

평균 재임 기간

45yo

평균 연령

경험이 풍부한 이사회: BLTE 의 이사회경험(평균 재직 기간 3 년)으로 간주됩니다.